KBC Group
RAPP icon

KBC Group’s Rapport Therapeutics RAPP Stock Holding History

KBC Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$32K Hold
962
– – ﹤0.01% 1800
2026
Q2 		$40K Hold
962
– – ﹤0.01% 1775
2026
Q1 		$30K Buy
+962
New +$27.1K ﹤0.01% 1799

Other funds holding RAPP

Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
Catalyst Private Wealth
Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

KBC Group's RAPP Position: Q3 2026 in Review

KBC Group held its Rapport Therapeutics (RAPP) position steady in Q3 2026 at 962 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #1800.

KBC Group first reported a position in RAPP in Q1 2026 and has held it in 3 quarters since. The position peaked at $40K in Q2 2026. 16 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • KBC Group held 962 shares of Rapport Therapeutics worth $32K as of Q3 2026.
  • KBC Group left its Rapport Therapeutics share count unchanged in Q3 2026.
  • Rapport Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1800 holding.
  • KBC Group first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • KBC Group's Rapport Therapeutics position peaked at $40K in Q2 2026.
  • 16 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.